Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2025 23:03 ET | Source: The Rosen Law Firm PA

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Iovance...
May 18, 2025 08:47 ET | Source: Faruqi & Faruqi LLP

IOVA Investors Have the Opportunity to Lead the Iovance Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options If you purchased or...
May 16, 2025 21:00 ET | Source: Bragar Eagel & Squire

IOVANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Encourages Investors to Contact the Firm

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Iovance...
May 16, 2025 12:16 ET | Source: The Law Offices of Frank R. Cruz

DEADLINE ALERT for CODI, ELV, and IOVA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, May 16, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded...
May 13, 2025 21:00 ET | Source: Bragar Eagel & Squire

IOVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Iovance Stockholders and Encourages Investors to Contact the Firm

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Iovance Biotherapeutics,...
February 16, 2024 15:19 ET | Source: Iovance Biotherapeutics, Inc.

Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma

AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune...
October 09, 2020 21:00 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Is Investigating Evolus, Lizhi, Iovance Biotherapeutics, and Y-mAbs Therapeutics and Encourages Investors to Contact the Firm

NEW YORK, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against on behalf of investors of Evolus,...
July 18, 2019 08:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer

SAN CARLOS, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on...